Medexus Pharmaceuticals Inc (MDP) AI Stock Analysis

• Market Cap: C$95.64M
• Dividend Yield: N/A
• Average Volume (3M): 46.68K
• Price to Earnings (P/E): 133.8
• Beta (1Y): 1.09
• Revenue Growth: 2.14%
• EPS Growth: -83.06%
• Country: CA
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 32,420,060
• 10 Day Avg. Volume: 30,861
• 30 Day Avg. Volume: 46,683
• PEG Ratio: -0.02
• Price to Book (P/B): 0.83
• Price to Sales (P/S): 0.40
• P/FCF Ratio: 2.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$6.00
• Price Target Upside: 107.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: C$3.00 ▲(3.81% Upside)

Medexus Pharmaceuticals Inc's overall stock score reflects mixed financial performance and weak technical indicators. The high P/E ratio suggests overvaluation, while the earnings call provides some optimism with successful product launches and reimbursement improvements. However, declining revenue and competitive pressures pose significant risks.

Positive Factors

New product adoption (GRAFAPEX)

GRAFAPEX's strong early adoption and $6.2M in six-month net revenue signal a durable new revenue stream. Management expects it to contribute positively to operating cash flow by Q3 2026 and NTAP reimbursement and high transplant center engagement support sustained uptake and commercialization scale.

Improving gross margins

A rising gross margin (55.7% vs 53.7%) indicates improved production economics or pricing power, supporting long-term profitability potential. Combined with manufacturing cost reductions on key products, this margin resilience helps absorb competitive pressures and supports sustainable cash generation.

Reduced leverage / stable balance sheet

Lower leverage (debt/equity 0.41) and a reasonable equity ratio provide financial flexibility for product launches and R&D. A stronger balance sheet reduces refinancing risk and supports strategic investments and commercialization efforts over the medium term, enhancing resilience.

Negative Factors

Declining revenue trend

A year-over-year revenue decline signals pressure on the company's top line which can erode scale advantages and margin leverage. Sustained revenue contraction limits reinvestment capacity and heightens reliance on new product launches to offset legacy product deterioration.

Weak operating cash conversion

Negative free cash flow growth and an OCF-to-net-income ratio of 0.25 indicate earnings are not being converted reliably into cash. This constrains funding for commercialization, R&D, and reduces margin of safety, increasing dependence on external financing for strategic initiatives.

Loss of exclusivity / generic competition

A 58% short-term drop in Rupall units after loss of exclusivity demonstrates how quickly revenue and pricing power can erode. Generic entry represents a persistent structural threat to legacy product cash flows and margins, requiring successful new-product commercialization to replace lost volume.

Medexus Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

How the Company Makes Money

Medexus Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include proprietary and licensed treatments for various conditions. The company has established key revenue streams through direct sales to healthcare providers and partnerships with other pharmaceutical companies for product distribution and co-marketing agreements. Additionally, Medexus benefits from government and private insurance reimbursements for its medications, which further contributes to its earnings. Significant partnerships with healthcare organizations and ongoing investment in research and development also play a crucial role in driving the company's revenue growth, as they enable Medexus to expand its portfolio and reach new markets.

Medexus Pharmaceuticals Inc Financial Statement Overview

Summary

Medexus Pharmaceuticals Inc shows a mixed financial performance. While there is operational efficiency and improved leverage, challenges remain in revenue growth and cash flow generation. The company needs to enhance profitability and cash flow to strengthen its financial position further.

Income Statement

Medexus Pharmaceuticals Inc shows a mixed performance in its income statement. The company has maintained a stable gross profit margin around 52%, indicating efficient production and pricing strategies. However, the net profit margin is low at 2.07% TTM, reflecting limited profitability. Revenue growth has been negative recently, with a decline of 2.46% TTM, which could be a concern for future earnings potential. The EBIT and EBITDA margins are moderate, suggesting operational efficiency but room for improvement.

Balance Sheet

The balance sheet reveals a moderate financial position. The debt-to-equity ratio has improved to 0.71 TTM from higher levels in previous years, indicating better leverage management. However, the return on equity is modest at 5.97% TTM, suggesting limited returns for shareholders. The equity ratio is not explicitly calculated, but the company's equity position has strengthened over time, which is a positive sign.

Cash Flow

Cash flow analysis shows some challenges. The free cash flow growth rate is negative at -20.50% TTM, indicating a decline in cash generation. However, the operating cash flow to net income ratio is healthy at 0.25, suggesting good cash conversion. The free cash flow to net income ratio is high at 0.89, indicating efficient cash utilization despite the decline in free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	104.10M	108.33M	113.05M	108.10M	76.70M	79.66M
Gross Profit	55.18M	56.58M	59.51M	60.04M	37.93M	42.01M
EBITDA	16.27M	16.81M	19.28M	16.14M	15.16M	-23.61M
Net Income	381.00K	2.25M	-214.00K	1.22M	-2.88M	-28.26M
Balance Sheet
Total Assets	149.44M	171.84M	155.73M	161.33M	139.22M	148.51M
Cash, Cash Equivalents and Short-Term Investments	9.38M	23.97M	5.25M	13.07M	10.02M	18.70M
Total Debt	21.07M	37.18M	49.90M	94.72M	54.86M	56.40M
Total Liabilities	97.02M	119.69M	125.41M	187.70M	151.82M	130.50M
Stockholders Equity	52.42M	52.14M	30.32M	22.45M	17.79M	18.02M
Cash Flow
Free Cash Flow	15.95M	21.31M	18.45M	-1.81M	-8.89M	-5.72M
Operating Cash Flow	16.24M	24.03M	18.71M	-1.44M	-1.18M	5.04M
Investing Cash Flow	-6.54M	-6.00M	-3.48M	-1.72M	-8.20M	-11.70M
Financing Cash Flow	-7.18M	796.00K	-23.05M	6.41M	663.00K	18.68M

Medexus Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Positive. The current price of 2.89 is above the 20-day moving average (MA) of 2.84, above the 50-day MA of 2.75, and above the 200-day MA of 2.80, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 53.02 is Neutral, neither overbought nor oversold. The STOCH value of 35.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MDP.

Medexus Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	76 Outperform	C$148.84M	17.29	22.35%	1.60%	22.22%	25.50%
VEXT	59 Neutral	C$69.35M	-2.37	-21.73%	―	43.56%	-349.41%
MDP	58 Neutral	C$95.64M	133.80	0.87%	―	2.14%	-83.06%
MPH	54 Neutral	C$12.52M	-3.59	-18.39%	―	24.30%	-68.60%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VM	46 Neutral	C$31.23M	-9.14	-256.01%	―	―	―
BNXT	42 Neutral	C$52.99M	-9.55	―	―	-62.34%	9.80%

Medexus Pharmaceuticals Inc Corporate Events

Medexus Secures New Credit Facilities and Plans Share Buyback

Medexus Pharmaceuticals announced a new senior secured credit agreement with National Bank of Canada, providing a US$21 million term loan and a US$5 million revolving loan, with additional features for future financing. This agreement allows Medexus to refinance its existing credit facilities, demonstrating its improving financial profile and access to competitive capital. Additionally, Medexus plans to initiate a normal course issuer bid for its common shares, subject to TSX approval, as part of its capital allocation strategy to potentially purchase up to 10% of its public float, aiming to enhance shareholder value and maintain market stability.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals Reports Strong GRAFAPEX Performance Amidst Revenue Challenges

Medexus Pharmaceuticals reported its fiscal Q2 2026 results, highlighting the strong performance of its product GRAFAPEX, which has exceeded expectations since its launch. Despite a decrease in overall net revenue due to competition and the termination of a previous agreement, GRAFAPEX’s success has positively impacted the company’s financials, with significant engagement from US transplant centers and expectations of accretive cash flows by Q4 2025. This positions Medexus well for future growth, despite challenges from generic competition affecting other products.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals to Discuss Q2 2026 Financial Results

Medexus Pharmaceuticals has announced a conference call scheduled for November 13, 2025, to discuss its second fiscal quarter results ending September 30, 2025. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market position and investor confidence.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.